topNational Stroke Research Institute
    NSRI     Research   Publications     Events    News
        ◀

Clinical Trial Research

Acute Stroke

Very Early Rehabilitation (VER) Stroke Research Program

are currently looking for acute stroke centres within Australia and Overseas to participate in AVERT Phase III. To find out more about the trial, please follow the link to A Very Early Rehabilitation Trial (AVERT): Protocol Synopsis Phase 3.

Reducing both the personal and community burden of stroke is a primary driver of the very early rehabilitation research program. Our research program has the largest randomised controlled trial of very early rehabilitation (AVERT) at its core. We aim to establish the efficacy, cost effectiveness and potential mechanisms of very early rehabilitation.

Key development objectives are to

  • Develop successful partnerships with professional organisations, policy makers, consumers, clinicians and researchers to promote real changes to clinical practice based on evidence
  • Become a world-class stroke research program
  • Publish significant research findings in high impact journals
  • Attract and supervise high quality national and international post graduate students
  • Increase capacity for high quality research within nursing and allied health disciplines
  • Develop new technologies for use in clinical research trials

To find out more please follow these links:

Program staff and students
Research opportunities for graduate students
Newsletter – Information for stroke patients and staff involved in AVERT Research Projects
A multicentre observational study of acute stroke units (AVERT Phase 1)
Safety and feasibility of very early rehabilitation (AVERT Phase 2)
A randomised controlled trial of very early rehabilitation (AVERT Phase 3)
What is very early stroke unit rehabilitation?
AVERT Online. A web based randomisation and trial management system

Enquiries about VER can be directed to the principal investigator, Dr Julie Bernhardt at avert@nsri.org.au.

A Very Early Rehabilitation Trial (AVERT): Phase 1

Bernhardt J, Dewey HM, Thrift AG, Donnan GA

Coordinating centre: National Stroke Research Institute

Participating centres: Patients and staff from stroke units at the Austin Hospital, Alfred Hospital, Royal Melbourne Hospital, St. Vincent's Hospital, and Western Hospital Melbourne, Australia.

Background: There is clear evidence that treatment in acute stroke units improves outcome, however, we know little about the components of care responsible for better outcomes.

Aims: To (i) document the level of physical activity in the acute stroke care unit; and (ii) examine the involvement of others on the physical activity of patients.

Study Design: Open observational study of patient activity and therapist report of patient interventions. A survey of stroke unit resources was also undertaken.

Method: Five metropolitan Melbourne stroke units participated. People less than 14 days from stroke onset and receiving an active therapy program were recruited. Ethics approval was obtained from each centre. Open observational behavioral mapping every 10 minutes for two consecutive therapeutic days from 08:00 to 17:00. Up to 25 categories were recorded at each observation period, including people present, location of activity and nature of activity. Treating therapists (physiotherapist, occupational therapists and speech therapists) provided a log of therapy preformed over both observation days. Senior staff completed a survey of stroke unit staffing resources.

Results and discussion can be obtained from publications (see below). The AVERT Phase 1 project was completed in December 2004.

Funding for this project was obtained from an NH&MRC Post Doctoral Fellowship (Julie Bernhardt) and an Austin Hospital Medical Research Fund seeding grant.

The following publications have arisen from this study to date:

  1. Bernhardt J, Dewey HM, Thrift AG, Donnan GA. Inactive and alone: Physical activity in the first 14 days of acute stroke unit care. Stroke. 2004; 35: 1005-1009.
  2. Bernhardt J, Chan J, Nicola I, Collier JM. Little therapy, little physical activity: Rehabilitation within the first 14 days of organised stroke unit care. Journal of Rehabilitation Medicine. In press, accepted 19/04/2006.

Enquiries about AVERT Phase 1 can be directed to the principal investigator, Dr Julie Bernhardt at avert@nsri.org.au.

A Very Early Rehabilitation Trial (AVERT): Phase 2

Bernhardt J, Dewey HM, Thrift AG, Donnan GA

Coordinating centre: National Stroke Research Institute

Participating centres: Patients and staff from stroke units at Austin Health and St. Vincent's Hospital, Melbourne, Australia.

Background: Very early rehabilitation, with an emphasis on mobilisation, may contribute to improved outcomes following stroke.

Aims: To evaluate the safety and feasibility of a very early rehabilitation (AVERT) protocol for patients managed in acute stroke units.

Study Design: A randomised controlled trial with concealed allocation, blinded assessment and intention to treat analysis.

Method: Patients less than 24 hours post stroke were recruited from two Melbourne metropolitan stroke units. Patients were randomly assigned to standard care or very early rehabilitation until discharge or 14 days (whichever was least). The primary safety outcome was the number of deaths at 3 months. Secondary safety outcomes were the rate of falls during the intervention period, failure to comply with physiological monitoring criteria and patient fatigue. Safety and efficacy outcomes were recorded at day 7, day 14, 3, 6 and 12 months.

Results and discussion: Recuitment ceased in February 2006, with 12 month follow-ups to be completed in February 2007.

Projects in development

  • Rehabilitation within 24 hours of stroke (AVERT). Results of a randomised Phase 2 trial. J Bernhardt, HM Dewey, AG Thrift, J Collier, GA Donnan.
  • Recovery in the first 14 days after stroke. A Lau, JM Collier, K Dodd J Bernhardt.
  • The effect of very early mobilisation on complications after stroke. D Sorbello, J Bernhardt, K Dodd, JM Collier.
  • Contamination of standard stroke unit care during a clinical trial. J Bernhardt, J Collier.

Predictors of recovery of walking following stroke

  • Relationship between early rehabilitation and quality of life during the acute post stroke phase of care.
  • Relationship between early rehabilitation and mood during the acute post stroke phase of care.
  • Changes to the ischaemic penumbra during standard care and very early rehabilitation.
  • The relationship between schedule of therapy and stroke outcome at 3 months.
  • The therapy schedule and perceived fatigue in acute stroke patients.

Funding for this project was obtained from an NH&MRC Post Doctoral Fellowship (Julie Bernhardt), Austin Health and Medical Research Foundation, National Heart Foundation, Affinity Health and Perpetual Trustees.

Enquiries about AVERT Phase 2 can be directed to the principal investigator, Dr Julie Bernhardt at avert@nsri.org.au.

A Very Early Rehabilitation Trial (AVERT): Protocol Synopsis Phase 3

Dewey HM, Bernhardt J, Donnan GA, Thrift AG, Carter R, Lindley R,

Coordinating centre: National Stroke Research Institute

Participating centres: To be confirmed.

 

Protocol Summary Version 1.0 – 4 April 2006

Download the protocol summary.

Publication:
Bernhardt J, Dewey H, Collier J, Thrift A, Lindley R, Moodie M, Donnan G. A Very Early Rehabilitation Trial (AVERT). International Journal of Stroke 1:169-171.

Projects in development
Health Economics - Validation of an early modified Rankin Score after stroke. H Zhao, J Bernhardt, JM Collier.

A comprehensive cost effectiveness study requires change scores on QOL measure. This study is required to determine whether the modified Rankin Scale can be employed day 0 post stroke.

Nursing - Nurses attitudes to involvement in research: Identifying barriers and solutions. This study will employ qualitative and quantitative methods to examine the evolution of attitudes to participation in research throughout the conduct of the very early rehabilitation trial.

Clinical Research - Physiological changes in response to very early rehabilitation compared to standard care.

Clinical Research - Does very early rehabilitation reduce lower limb spasticity and muscle length changes early after stroke?

Basic Science - Examining the effect of the timing and scheduling of exercise on functional and anatomical outcomes using a rat stroke model.

Funding for this project has been obtained from the Australian National Health and Medical Research Council.

Enquiries about AVERT Phase 3 can be directed to the principal investigator, Dr Julie Bernhardt at avert@nsri.org.au.

What is very early stroke unit rehabilitation? A comparison of physical activity patterns in Melbourne, Australia and Trondheim, Norway

Bernhardt, N Chitravas, I Lidarende, A Thrift, B Indredavik

Coordinating centre: National Stroke Research Institute

Participating centres: Patients and staff from stroke units in Melbourne Australia (Austin Hospital, Alfred Hospital, Royal Melbourne Hospital, St. Vincent's Hospital, and Western Hospital Melbourne) and Trondheim, Norway (St. Olav’s Hospital).

Background: It has been shown that very early mobilisation may be an important cause of the very favourable results of stroke unit care in Trondheim, Norway.

Aim: To (1) describe and compare the pattern of physical activity of stroke patients between stroke units in Trondheim and Melbourne; and (2) identify differences in activity according to stroke severity between the two sites.

Study Design: Between groups comparison.

Methods: Melbourne patients were recruited from five metropolitan stroke units Trondheim patients were recruited from the stroke unit at University Hospital, Trondheim. People less than 14 days from stroke onset and receiving an active therapy program were recruited. Ethics approval was obtained from each centre. Open observational behavioural mapping every 10 minutes over a single therapeutic day from 08:00 to 17:00. Up to 25 categories were recorded at each observation period, including people present, location of activity and nature of activity. Treating therapists (physiotherapist, occupational therapists and speech therapists) provided a log of therapy preformed over both observation days. Senior staff completed a survey of stroke unit staffing resources. Logistic regression analyses were undertaken to assess differences in physical activity patterns between stroke units in the two cities.

Results and discussion are underway.

Funding: NH&MRC of Australia (157305), an Austin Hospital Medical Research Fund seeding grant, and travel grants from the Ian Potter Foundation and the Stroke Society of Australasia.

Enquiries about this study can be directed to the principal investigator, Dr Julie Bernhardt at avert@nsri.org.au.

COLLABORATION WORKS! LINKING STROKE RESEARCHERS AND SOFTWARE ENGINEERING STUDENTS TO CREATE AVERT ONLINE

The AVERT Online Team

Coordinating centres: National Stroke Research Institute*, RMIT University†

The AVERT Online Team:  Jesse Jackson†, Edwin Leong†, Tommy Li†, Naomi O’Neil†, Alan Ta†, Janice Collier*, Li Chun Quang*, Julie Bernhardt*

Background: AVERT (A Very Early Rehabilitation Trial) Phase 3 is an investigator driven, multicentre, randomised controlled trial of very early rehabilitation. Trial quality depends on effective and efficient systems for randomisation, data collection and communication across multiple hospital sites. As a trial with a big agenda but a small budget, we needed to find creative ways of developing the information technology trial resources. We approached RMIT University to help develop AVERT Online, a web-based system for trial administration.

Method: Five software engineering students developed AVERT Online as part of their final year elective. AVERT Online uses a centralised web portal accessible through an Internet browser. It consists of an intuitive patient management user interface, online address book for effective communications, reminder module to assist in administrative tasks and an automated import module for acquiring trial data from external sources. Summary reports can also be generated on trial progress.

Results and Conclusions: The system design and user interface are complete. Final testing is underway. AVERT Online will be deployed in July 2006 for the very early rehabilation trial, Phase 3. This collaboration has produced a vital tool for AVERT and provided valuable industry experience for students who have used industry best practice for software development.

Enquiries about AVERT Online can be directed to the principal investigator, Dr Julie Bernhardt at avert@nsri.org.au.

AVERT Online link: https://www.avertonline.org.au/login.php

 

.............................................................................................................................................................................................................

Drug Trials

MINT (Minocycline in Neuroprotection)          click here for MINT online website

Stroke affects approximately 46,000 thousand Australians every year and the therapeutical options are limited.

Minocycline is a lipophilic semi-synthetic tetracycline that easily crosses the blood-brain barrier. In 1977 its antiinflammatory properties were described for the first time and in 1998 it’s been used for the first time in acute stroke animal models. Since then, many studies have been performed in animals and a few phase I and phase II have been published for other neurological conditions such as Huntington disease, amyotrophic lateral sclerosis and multiple sclerosis.

Data from an unpublished meta-analysis showed that in stroke animal models minocycline has a beneficial effect in reduction of final volume of the lesion in different doses and time windows. The use of minocycline in conjunction with standard stroke therapeutic approaches (aspirin and rtPA) has also been proved to be safe in animal studies.

MINT is a randomized placebo-controlled double blinded phase II trial for assessing the safety and feasibility of the use of minocycline for neuroprotection for acute ischaemic and haemorrhagic stroke patients.

  • Primary outcome measures
    • Mortality in 90 days
    • Reduction of serum level of one anti-inflammatory marker
    • Completion of enrolment of all the patients
  • Secondary
    • Liver function
    • Other significant adverse event
    • Clinical outcome at 90 days (NIHSS, mRS, Barthel)

    Inclusion criteria
    • Males and females aged ≥ 18
    • Able to give consent or to be given by person responsible
    • Signs and symptoms of acute stroke with consistent CT/MRI
    • Ability to receive study medication within 24 hours of symptoms onset
  • Exclusion criteria
    • Image suggestive of non-vascular disorders
    • GCS of 5 or less
    • No measurable deficit on NIH stroke score (NIHSS)
    • Haemoglobin <100g/L, platelet count <75x109/L or neutrophil count < 1.0x109/L
    • Serum creatinine ≥ 1.2 x ULN
    • Serum ALT > 3 x ULN or bilirubin > 1.5 x ULN
    • Pregnancy or breastfeeding at the time of study entry
    • Evidence of other severe or uncontrolled disease
    • Previous investigational agent within 30 days
    • Evidence of clinical disorder or laboratory finding that makes it undesirable to enrol the patient in the study
    • Known seropositive to HIV, HCV or Hepatitis

OPEN LABEL tPA

EPITHET

To determine whether the extent of the ischemic penumbra apparent on perfusion-diffusion MRI can be used to identify patients who would respond positively and safely to tissue plasminogen activator (tPA) beyond 3 hours post-stroke.

DIAS II

To further investigate the clinical efficacy and safety of two different dosages of recombinant desmoteplase (vampire bat plasminogen activator) in acute ischemic stroke.

SAINT II

To assess the efficacy and safety of intravenous NXY-059 in acute ischemic stroke within six hours of symptom onset.

ANCROD

To compare ancrod (purified fraction of pit viper venom) verses placebo in the treatment of ischemic stroke patients.

IST3

To determine whether administration of recombinant tissue plasminogen activator (r-tPA) within 6 hours of ischemic stroke increases the proportion of independent survivors at 6 months.

ENOS

To assess the risks and benefits of administering transdermal nitrous oxide immediately after ischemic and hemorrhagic stroke, and to determine whether or not to continue anti-hypertensive medication taken prior to stroke.

INTERACT

A preliminary trial that will assist to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral hemorrhage) will reduce the chances of a person dying or surviving with a long term disability.

BASICS

The development of a database to obtain sufficient information about the response of basilar stroke patients to various therapies to eventually design a randomized controlled trial.

FAST

To determine if the treatment of Recombinant Factor VIIa in patients with acute intracerebral bleeding will help more patients recover without severe permanent disability by reducing further intracerebral bleeding.

CHIL

The aim of this pilot study is to determine whether induced moderate hypothermia in patients with acute severe stroke is: (a) rapidly attainable and sustainable for 48 hours by infusion of refrigerated fluids and surfacing cooling techniques including ice, fanning, and cooling blankets; (b) safe as measured by infectious complications, hypotension, clotting abnormalities, arrhythmias/serious heart dysfunction, electrolyte disturbances; (c) a viable treatment alternative as judged by patient acceptance and staff compliance with the treatment protocol (ie well tolerated); and (d) potentially efficacious as judged by comparison of clinical outcome with historical controls.

 

.............................................................................................................................................................................................................

Secondary Prevention

ONTARGET

To compare the prophylactic efficacies of an angiotensin II receptor blocker (telmisartan), an ACE inhibitor (ramipril), and the two drugs used in combination, against major cardiovascular events in high-risk patients.

DICE

To assess the prophylactic efficacy of dextran against postoperative thromboembolic stroke following carotid endarterectomy (CEA). (Link to DICE Protocol)

ARCH

To compare the efficacy of anticoagulant therapy (warfarin) with that of anti-platelet therapy (aspirin in combination with clopidogrel) in preventing stroke in high-risk patients with aortic arch atheromas.

PROFESS

To compare the efficacy and safety of Aggrenox®(25 mg aspirin/200 mg extended-release dipyridamole) with Clopidogrel (Plavix®), and to compare Micardis® (telmisartan) with placebo in in the presence of background anti-hypertensive treatment in the prevention of recurrent stroke.

PERFORM

To investigate the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack.

VITATOPS

To determine whether lowering plasma homocysteine concentrations by the administration of vitamin supplements (folic acid 2 mg, B6 25 mg, B12 500 g) will reduce the incidence of vascular sequelae following recent stroke or transient ischemic attacks (TIA).

ICSS

To compare the risks and benefits of primary carotid stenting with those of conventional carotid endarterectomy in patients at high risk for stroke.